The Alter Pharma Group is excited to announce its rebranding, uniting all its brands and businesses. We were already sharing One Mission, and now we also share one brand, one name: A.forall. This change represents an important milestone in A.forall’s pursuit of a world where patients can access high-quality, safe and innovative medicines at an affordable price and strengthens A.forall’s commitment to #MakingAffordableMedicinesAvailableToAll, offering new synergies and ways to leverage the skills and capacities of its 144 employees around the world. “A.forall” is more than a name: it’s a promise – for Accessibility, for Assurance, and for All – a pledge to make healthcare...
News
Company millestone: Milla Pharmaceuticals Receives FDA Approval for Dexmedetomidine Hydrochloride Injection
We are proud to announce that it has received FDA approval for its generic version of Precedex®, Dexmedetomidine Hydrochloride Injection. The product is set to launch very soon. Dexmedetomidine Hydrochloride Injection plays a vital role in sedating patients who are initially intubated and mechanically ventilated during intensive care treatment. Administered through continuous infusion for a maximum duration of 24 hours, it offers effective sedation. Notably, Dexmedetomidine Hydrochloride Injection is currently experiencing supply issues and is listed on the FDA’s Drug Shortages list. This recent approval will significantly contribute to alleviating the supply challenges faced in the U.S. This accomplishment marks...
Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of Generic Version of Magnesium Sulfate in Water for Injection
Milla Pharmaceuticals successfully partnered with Athenex Pharmaceutical Division (APD) to release a generic version of Magnesium Sulfate in Water for Injection. The U.S. Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) for Magnesium Sulfate Injection, which is currently on the ASHP Drug Shortages List . The product is intended to prevent and control seizures in preeclampsia and eclampsia, and the launch aims to address recent supply issues for the medication in the U.S. market. Erik Lazarich, President of the US Operations of the Alter Pharma Group and Director of Milla Pharmaceuticals, said, “By launching our...